European Medical Agency - Rixathon

European Medical Agency - On 21 April 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rixathon, intended for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

Bloodwise Patient Need Survey

As you may have seen Bloodwise have recently launched a survey to help ensure that all blood cancer patients have access to services that help them live well with and beyond their cancer. They are starting by looking to identify any gaps in the current Cancer Recovery Package, understanding levels of awareness and usage of the package.